The role of topoisomerase [IIA] as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

8^th Euro Global Summit on Cancer Therapy

November 03-05, 2015 Valencia, Spain

A. Barakat1, F. Zakaria2, M.Alm3, M.Gamea4

123University of tanta, Egypt, 4Gharbia Cancer Society, Egypt

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Background: Surrogate markers may be used to assess the response toneoadjuvantchemotherapy.Thepurpose of the study was to evaluate topoisomerase II�± as predictive factor for response to neoadjuvantanthracyclines based chemotherapy in locally advanced breast cancer patients. (1) tumour grade scored according to the Elstonâ��Ellis classification, (2) hormonalreceptor (HR) status, (3) tumour cell proliferation evaluated by Ki-67 staining, (4) HER-2 and topoisomerase II alpha (TopoIIa) expression evaluated byimmunohistochemistry (IHC). Method: Between January 2012 andjune 2012, 50 locally advanced breast cancer patients had received 3 cycles neoadjuvant chemotherapy were studied in clinical oncology department at tanta university. Regimens including either CEF (cyclophosphamide 500mg/m2,epirubicin100mg/m2, 5-fluorouracil 500mg/m2) or FAC(cyclophosphamide500mg/m2,doxorubicin 50mg/m2, 5 fluorouracil 500mg/2). Protein expression of HER2and Topo II�± were determined by immunohistochemistry. The primary endpoint was pathological and clinicalTumour responsethat assessed clinically and bymamography, then by pathological assessment. Results: Of 50 primary locally advanced breast cancer patients had been assessed after 3 cycles of NACT, the clinical complete response was in 6% (3/50), clinical partial response was in 86% (43/50) and overall clinical response was 92% (46/50), 4 (8%) patients had clinical stable disease and no one developed disease progression. 1-Responders had the following biomarkers criteria: Clinical (CR): 3 patients had co-expression of topo II and HER2, hormonal receptor negative and high KI-67. Clinical(PR):43 patients majority of them had topo IIA overexpression . 2-Non responders had the following criteria: 4(8%) patients all had negative (TOPOII/HER2), low KI-67and 2 had hormonal receptor positive and another 2 had hormonal receptor negative. Conclusion: Our study suggests that HER2 and Topo II�± overexpression could be predictors of the response toneoadjuvantchemothrapy in both the CEF and FAC arms.